Novel Health Strategies team is presenting nineteen studies at ISPOR 2103 Annual Meeting in New Orleans on market access strategy, pricing and health economic and outcomes research trends.
These studies were led by Novel Health team and are good examples of wide breadth and depth of our expertise.
In-person replays of all presentations are available upon request.
Meta-Analysis for Efficacy of Romiplostim for Treatment of ITP
Trends in Cost Effectiveness of High Budget Impact Products
PROs in Glaucoma a Systematic Review
PROs in Chronic Myeloid Leukemia: A Systematic Review
PROs in Castration-Resistant Prostate Cancer: A Systematic Review
Meta-Analysis For Efficacy of Etanercept For Treatment of Psoriatic Arthritis
Novel Electronic PROs Tool for Prostate Cancer Patients
Budget Impact Model for CTCL
Systematic Review of Anti-VEGF Therapies for Metastatic CRC
In-Patient Hospitalization Trends for CKD in the United States
Meta-Analysis for Safety of Dabigatran and Warfarin for Treatment of Atrial Fibrillation
Reimbursement and Market Access of MS Products in the United States
Cancer Drug Pricing Trends in the US and the UK (2011-2013)
Novel Reimbursement Models for Cancer Drug Market Access (2010-2013)
Trends in Use of Health Economic Evidence for Developing Clinical Guidelines
Review of France's Transparency Committee's 2011-2012 Assessments
Pricing and Reimbursement of Targeted Cancer Therapies in Russia (2011-2012)
Biosimilars Pricing Dynamics in Big Five European Union Countries (2011-2012)
Role of Subgroup Analyses for Health Technology Assessments